MiniMed Group, Inc. (MMED)
| Market Cap | 4.33B |
| Revenue (ttm) | 3.10B +14.3% |
| Net Income | -333.00M |
| EPS | -1.30 |
| Shares Out | 280.84M |
| PE Ratio | n/a |
| Forward PE | 23.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 909,406 |
| Open | 15.18 |
| Previous Close | 15.04 |
| Day's Range | 15.03 - 15.84 |
| 52-Week Range | 10.65 - 20.48 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.91 (+35.6%) |
| Earnings Date | Aug 10, 2026 |
About MMED
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company’s platform includes Automated Insulin Delivery (AID) systems for... [Read more]
Financial Performance
In fiscal year 2026, MiniMed Group's revenue was $3.10 billion, an increase of 14.25% compared to the previous year's $2.72 billion. Losses were -$333.00 million, 56.3% more than in 2025.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for MMED stock is "Strong Buy." The 12-month stock price target is $20.91, which is an increase of 35.60% from the latest price.
News
MiniMed adds David Endicott, Linnea Burman to board of directors
MiniMed (MMED) announced that David Endicott and Linnea Burman have joined its Board of Directors, effective June 29, expanding the Board from nine to 11 members. Endicott will serve as…
MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
David Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experience; Linnea Burman adds MedTech operating depth NORTHRIDGE, Calif., June 29, 2026 /PRNew...
MiniMed launches Instinct sensors in Europe
MiniMed (MMED) announced the commercial launch in Europe of both the MiniMed 780G system integrated with the Instinct sensor and the MiniMed Go system integrated with the Instinct Go sensor.
MiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes
MiniMed automated insulin delivery and smart MDI systems can now be paired with Instinct and Instinct Go, made by Abbott, the smallest, longest-wear sensors in the company's portfolio NORTHRIDGE, Cali...
MiniMed announces commercial launch of MiniMed Flex system in the U.S.
MiniMed (MMED) announced its first commercial launch of the MiniMed Flex system in the U.S.- its first app-controlled pump and the company’s smallest insulin pump yet. The system launches with…
MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.
People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor NORTHRIDGE, Calif., June 17, 2026 /PRNewswire/ -- MiniMe...
MiniMed Group Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
AID systems are driving market growth, with new product launches and a robust pipeline supporting both U.S. and global expansion. The company leverages an integrated technology platform, direct commercial presence, and disciplined financial strategy to maintain competitive advantage and deliver sustained growth.
MiniMed Group Slides: Investor presentation
MiniMed Group has posted slides in relation to its latest quarterly earnings report, which was published on June 6, 2026.
MiniMed price target lowered to $22 from $26 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on MiniMed (MMED) to $22 from $26 and keeps an Overweight rating on the shares following the first earnings report…
MiniMed Group Earnings Call Transcript: Q4 2026
Record fiscal 2026 revenue surpassed $3 billion, with 8% organic growth and strong international performance. New product launches and pipeline advancements underpin a 10% organic growth outlook for FY 2027, with EBITDA margin expansion expected.
MiniMed Group Earnings release: Q4 2026
MiniMed Group released its Q4 2026 earnings on June 3, 2026, summarizing the period's financial results.
MiniMed Group Slides: Q4 2026
MiniMed Group has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 3, 2026.
MiniMed Group Annual report: Q4 2026
MiniMed Group has published its Q4 2026 annual report on June 3, 2026.
MiniMed announces expanded ketone sensor agreement with Abbott
MiniMed (MMED) announced an expanded agreement with Abbott (ABT) to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems. Thes...
MiniMed reports Q4 EPS (68c), consensus (22c)
Reports Q4 revenue $837M, consensus $826.52M. “MiniMed (MMED) delivered a strong finish to our fiscal year, driven by strength in international markets and continued global adoption of the MiniMed 780...
MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott
Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in dia...
MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook
Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year Record annual net sales performance surpasses $3B for first time, growing 14% as reported...
MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions
Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data NORTHRIDGE, Calif., May 27, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a g...
MiniMed to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
NORTHRIDGE, Calif., May 26, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in a fireside chat at the upcoming Gol...
New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System
Randomized crossover trial reinforces SmartGuard™ algorithm as key driver of automated insulin delivery performance NORTHRIDGE, Calif., May 21, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global le...
MiniMed price target lowered to $20 from $27 at BofA
BofA analyst Travis Steed lowered the firm’s price target on MiniMed (MMED) to $20 from $27 and keeps a Buy rating on the shares. After having hosted 34 medtech companies…
MiniMed Aims to Be 'Self-Driving Car' of Diabetes Care
Diabetes equipment provider MiniMed is aiming to be the “self-driving car” of insulin pumps, says its CEO, Que Dallara. Hot off the heels of the company's IPO, Dallara speaks with Caroline Hyde on the...
MiniMed initiated with a Buy at Benchmark
Benchmark last night initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target MiniMed is the only company with an “across-the-board strategy” for diabetes management, offering conti...
MiniMed initiated with a Buy at Benchmark
Benchmark initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target
MiniMed 780G system software licensed by Health Canada
MiniMed (MMED) announced Health Canada has licensed new software for the MiniMed 780G system. Additionally, the system is now compatible with Fiasp and indicated for adults 18 years and older…